No Data
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated With Pemvidutide at The Liver Meeting 2024
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Analysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Hansa Biopharma AB (SE:HNSA)
Obesity Drugs Seen Costing Medicare $35 Billion Through 2034
Piper Sandler Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25